Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
about
Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.The structural basis for cancer treatment decisions.Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.An approach to the management of chronic myeloid leukemia in British Columbia.Molecular biology of bcr-abl1-positive chronic myeloid leukemia.Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia.Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia.Characterization of cryptic rearrangements, deletion, complex variants of PML, RARA in acute promyelocytic leukemia.Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.FISH mapping of Philadelphia negative BCR/ABL1 positive CML.A rare case of Philadelphia chromosome-positive chronic myelogenous leukemia with inversion in chromosome 9 and t(10;17).Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.Molecular diagnostics in chronic myeloid leukemia.Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.Downregulated expression of genes mapping on chromosome 9 in chronic myeloid leukemia cases bearing genomic deletions on der(9)Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
P2860
Q33919931-14E9DEF5-E170-48E6-AD5C-D10CBB4C0651Q34365654-4AA65BC2-547D-4E50-902F-CA11454DD4F6Q35073935-A8345E60-9ABF-415C-873A-1686649443D9Q35849776-A17EF94D-80A2-49C6-9BF0-697942484F44Q36153422-9036D1EC-4231-4081-BD14-3BF43BAEA69CQ36362047-9A3CA3C7-0709-4BCD-BC6F-88295E97FC7EQ36364850-75D839A7-1C2C-482C-83FE-BBC48A9F755CQ36627268-6D3E789C-9367-44BD-A1F3-A053C392D4FEQ37283128-D12AB7DC-3317-4E49-A993-EF75247EA23BQ37424789-5A4CC17A-8EEA-4EC5-8722-B5ADE55909A2Q37428659-CFE7DDDD-FDAC-4062-B4DF-626F98E8E173Q37836922-19C2B30F-6102-43A2-A964-7E0C7E4F48DDQ38476431-46AF1C68-2D7F-4A67-90A3-E257449548F2Q39047626-16BD0852-5F60-49FB-8816-B3C47D91F4B1Q39464336-4F91A183-D6C3-48AF-9397-F207B680E4B5Q39959667-9A1199CF-CF14-4AA1-9DA7-54E127CAD7C3Q42089789-C60AAE9B-C064-40C0-8151-78653D530209Q42975088-0258E4B5-40EB-47E1-A304-6843369FEB43Q44453492-82CFF1AA-38F4-41D4-9E3E-30BB1CA7FDDEQ45991048-EE51893F-59DE-438D-8D8A-347BE92477F2Q45991055-AFF57DCE-93AA-44A8-9A0E-993288DBC523Q53178315-086920FA-5498-401A-9948-2CAF0DF8A1B5Q54599105-CAD118C1-59FD-4C8F-9943-495B13C4949EQ57690174-C22EB666-F7ED-4A67-9B58-8BF21677B91CQ58010946-B2755068-D2F4-4C78-A93E-76E2E0595169
P2860
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Imatinib mesylate therapy may ...... chronic myelogenous leukemia.
@en
Imatinib mesylate therapy may ...... chronic myelogenous leukemia.
@nl
type
label
Imatinib mesylate therapy may ...... chronic myelogenous leukemia.
@en
Imatinib mesylate therapy may ...... chronic myelogenous leukemia.
@nl
prefLabel
Imatinib mesylate therapy may ...... chronic myelogenous leukemia.
@en
Imatinib mesylate therapy may ...... chronic myelogenous leukemia.
@nl
P2093
P50
P1433
P1476
Imatinib mesylate therapy may ...... chronic myelogenous leukemia.
@en
P2093
Armand Glassman
B Nebiyou Bekele
Kimberly Hayes
Moshe Talpaz
P304
P356
10.1182/BLOOD-2004-06-2208
P407
P50
P577
2004-11-30T00:00:00Z